Background
==========

In May 2017, the International Society of Hypertension (ISH) introduced the first in a series of annual blood pressure (BP) screening programmes with the simple aim of raising awareness of the importance of raised BP as the single biggest contributor to the global burden of disease and to global mortality.[@suaa013-B1]

After the success of this initial May Measurement Month (MMM) campaign---which included over 1.2 million screenees from 80 countries,[@suaa013-B2] MMM expanded in 2018 and again in 2019. The global results of MMM17 and MMM18 have been published elsewhere[@suaa013-B2]^,^[@suaa013-B3] and the national data from 39 of 40 countries who screened at least 2500 adults in 2017 were collated as a *European Heart Journal (EHJ) Supplement*.[@suaa013-B4] Here, we present a second collation of data from 41 countries with the highest number of participants who took part in MMM18.

MMM18 summary
=============

The methods and results of MMM18 were published in full elsewhere.[@suaa013-B3] As in 2017, the MMM18 campaign was a cross-sectional opportunistic survey of the BPs of adults (aged ≥18 years) who wished to take part. Three sitting BPs were measured on each screenee in any of a wide range of locations from places of worship to hospital premises. Limited data on social, demographic, and lifestyle variables were also recorded and for those whose BPs (using the mean of the second and third reading) were deemed potentially in the hypertensive range (systolic ≥140 mmHg and/or diastolic ≥90 mmHg) were given non-pharmacological advice to lower their BP and advised to seek further BP recordings on a time scale depending on the degree of BP elevation and the availability of local healthcare facilities.

Over 1.5 million adults were screened in 89 countries of whom 33.4% were considered hypertensive (BPs in the hypertensive range and/or on antihypertensive medication to lower BP). Among the hypertensive population, 55.3% were on antihypertensive medication and of those 60.0% had their BPs controlled to \<140 mmHg systolic and \<90 mmHg diastolic. Therefore, of 502 079 hypertensive adults identified overall, 33.2% had their BPs controlled and over one-third of a million adults were identified with either untreated or inadequately treated raised BP. MMM18 was the largest synchronized and standardized survey of any cardiovascular risk factor ever to take place (with MMM17 the next largest!). The vast majority of those screened in MMM18 were new to MMM, with only 7.0% having participated in MMM17. Furthermore, over half a million people (518 168) reported never having had a BP measurement taken before the campaign.

From global to national data in MMM18
=====================================

In order to bring focus at a more local level around the world, but at the same time include reasonably valid data observed at a national level, those 42 countries who had screened at least 2500 adults were invited to report their data for compilation in this *EHJ Supplement*. Forty-one countries accepted this invitation and have been included. The key results across these countries are summarized in *Table [1](#suaa013-T1){ref-type="table"}*.

###### 

National MMM18 results summary with total participants from MMM17 for comparison

  Country                        Total participants 2017   Total participants 2018   Number with hypertension   Proportion with hypertension (%)   Proportion of hypertensives aware (%)   Proportion of hypertensives on medication (%)   Proportion of those on medication with uncontrolled BP (%)
  ------------------------------ ------------------------- ------------------------- -------------------------- ---------------------------------- --------------------------------------- ----------------------------------------------- ------------------------------------------------------------
  India                          122 685                   345 234                   111 462                    32.3                               56.9                                    55.3                                            25.3
  China                          125 236                   288 342                   85 835                     29.8                               62.3                                    57.3                                            37.4
  Philippines                    271 604                   177 176                   69 126                     39.0                               50.3                                    49.9                                            42.0
  Indonesia                      69 307                    91 222                    27 331                     30.0                               47.6                                    47.4                                            78.0
  Argentina                      32 346                    70 418                    30 851                     43.8                               77.7                                    69.1                                            44.0
  Kenya                          14 847                    49 548                    8469                       17.1                               30.7                                    26.6                                            51.0
  Sudan                          44 413                    40 779                    11 497                     28.2                               20.7                                    18.2                                            45.4
  Colombia                       22 258                    35 548                    9475                       26.7                               69.9                                    65.0                                            33.7
  United Arab Emirates           6193                      31 316                    6243                       19.9                               40.7                                    37.3                                            39.4
  Venezuela                      21 645                    28 649                    13 861                     48.4                               87.7                                    82.6                                            33.7
  Pakistan                       5333                      25 076                    14 641                     58.4                               79.9                                    73.5                                            51.4
  Armenia                        9199                      21 112                    8179                       38.7                               76.7                                    67.4                                            52.9
  Democratic Republic of Congo   Not included              18 719                    4885                       26.1                               46.3                                    29.6                                            57.0
  Vietnam                        10 993                    17 332                    5260                       30.3                               66.4                                    62.8                                            46.6
  Nepal                          5972                      15 561                    4321                       27.8                               49.9                                    39.1                                            47.4
  Taiwan                         52 514                    15 365                    7393                       48.1                               83.7                                    81.3                                            32.3
  Angola                         17 481                    14 433                    4844                       33.6                               54.2                                    46.3                                            57.4
  Oman                           934                       12 689                    3783                       29.8                               52.4                                    47.8                                            34.9
  Brazil                         7260                      12 413                    8435                       67.9                               84.4                                    81.7                                            40.3
  Ecuador                        6984                      11 922                    4563                       38.3                               71.5                                    71.5                                            28.6
  Malawi                         4009                      10 791                    2404                       22.3                               14.7                                    12.6                                            33.3
  Georgia                        6144                      10 756                    6037                       56.1                               82.8                                    77.9                                            61.8
  Mexico                         1116                      10 139                    2187                       21.6                               42.0                                    38.0                                            33.5
  Chile                          4754                      9344                      2726                       29.2                               64.0                                    56.1                                            38.0
  Cameroon                       16 093                    8883                      1867                       21.0                               34.5                                    27.2                                            52.2
  Cabo Verde                     2630                      8008                      2666                       33.3                               74.8                                    55.8                                            60.9
  Spain                          3849                      7646                      3058                       40.0                               74.4                                    69.6                                            36.4
  Libya                          Not included              7279                      2567                       35.3                               63.4                                    55.8                                            49.1
  Albania                        1008                      7046                      2624                       37.2                               52.1                                    48.3                                            49.6
  Ghana                          Not included              6907                      2354                       34.1                               48.4                                    35.2                                            52.2
  Poland                         5834                      6450                      2114                       32.8                               61.3                                    53.1                                            39.2
  Nigeria                        19 904                    6398                      2328                       36.4                               51.1                                    41.8                                            56.9
  Republic of the Congo          3842                      6169                      1371                       22.2                               40.2                                    36.0                                            55.5
  Italy                          10 076                    5554                      1462                       26.3                               [^a^](#tblfn1){ref-type="table-fn"}     [^a^](#tblfn1){ref-type="table-fn"}             [^a^](#tblfn1){ref-type="table-fn"}
  Mauritius                      2302                      5471                      786                        14.4                               [^a^](#tblfn1){ref-type="table-fn"}     [^a^](#tblfn1){ref-type="table-fn"}             [^a^](#tblfn1){ref-type="table-fn"}
  Bangladesh                     11 418                    5208                      1750                       33.6                               75.0                                    64.7                                            33.6
  United Kingdom and Ireland     7714                      5000                      1716                       34.3                               51.3                                    42.8                                            48.5
  Slovenia                       Not included              4883                      2841                       58.2                               78.4                                    70.1                                            51.5
  Malaysia                       4116                      4866                      1405                       28.9                               76.3                                    71.0                                            37.6
  Botswana                       1657                      4599                      1510                       32.8                               47.1                                    35.2                                            45.6
  Australia                      3817                      3352                      1026                       30.6                               49.0                                    40.5                                            57.1
  South Africa                   3250                      2965                      1025                       34.6                               56.7                                    49.2                                            42.5

Use of antihypertensive medication not recorded for these countries.

The protocol for MMM18 was common to all participating countries and so the methods for each country are essentially the same. However, data from previously available BP screening in each country vary as did the logistics and the sources of the convenience samples screened. These details potentially impact significantly on the interpretation of the results obtained in each country and the observed differences among them.

Methodological issues
=====================

Usually for logistical reasons, the data on some variables in some countries were insufficient in quality or number for analyses to provide reasonably valid results and hence they were not carried out.

However, even when carried out, given 41 separate national analyses chance alone would predict two significantly inconsistent results when compared with the global analyses. Hence, comparisons across countries should only be made with extreme caution.

Importantly, three seated BP measurements could not always be taken and so multiple imputation based on the global data[@suaa013-B3] was used to generate the mean of the second and third BP readings in the analyses, for the 375 427 people (25.2%) for whom the mean readings were not available. Our previous analyses showed that this combination of readings gave the most conservative estimate of hypertension prevalence which is likely to be spuriously elevated when based on a single set of readings.[@suaa013-B3]

For these national-level analyses, we have used the same imputed data from the global analyses which may result in an 'averaging' of any country-specific effects, as for many countries, there were insufficient data to allow individual imputations. Two imputation models were run: a full model requiring complete information on participants age, sex, ethnicity, and use of antihypertensive medication, and where one or more of these were missing, a reduced model, requiring only individual BP readings. Imputations using the two models were combined, and sensitivity analyses showed only small differences between the results using each model.

The national data presented in this supplement tend to give focus to those measures of association which differ from the reported global findings[@suaa013-B3] despite the cautions outline above. Meanwhile less focus is placed on those associations---particularly those between BP and age, sex, and body mass index---that are essentially consistent across countries and with the global results.

Challenges for MMM18
====================

Having carried out MMM17, the set up and running of MMM18 was less time-pressured and was easier to conduct at both local and central levels. Most national coordinators and volunteer staff in each country were already in place from MMM17 (and prepared to be involved again) but even so, ethical clearance remained a major hurdle in some countries. Similarly, the distribution of the BP machines, kindly donated by OMRON Healthcare, caused variably large difficulties associated with customs charges and delays in delivery.

Data collection and delivery for central analyses were greatly improved in terms of quality and quantity compared with MMM17. However, the use of the MMM App (available on Windows and Mac computers, Android, and Apple mobile devices, as well as a web-based browser) remained low at 12.4% and central data cleaning remained a large task, taking several months. Consequently, once again we were only able to lock the database and initiate the full analyses in October 2018---nominally 5 months after MMM18 ended.

Limitations of MMM
==================

Feedback from local investigators who participated in MMM17 included a request not to extend the amount of data collected from each participant due to the extra time needed during the screening. Consequently, data from MMM18 remain limited to BP and heart rate measurements and self-reported observations, while blood and urine sampling or more sophisticated measurements of obesity, for example, were beyond the capacity of the personnel and budget for the campaign.

For similar reasons and also by design, the samples screened were not randomly selected and therefore not necessarily representative of the general population from which they were drawn. While standardizing of results could partially account for differences in the age and sex distributions amongst those screened in each country, there is likely to be residual confounding, most notably a selection bias resulting from the recruitment method and a potential favouring of those with pre-existing hypertension or with greater hypertensive awareness, to participate. Consequently, in order not to mislead that the proportions found to be hypertensive, or on treatment for hypertension may be directly comparable, we present in each paper the unadjusted proportions within each country.

It might, however, be less unreasonable to compare control rates among treated patients, since, by stratifying on one of the major confounding factors, we may reduce some of the sampling bias. These potential shortcomings notwithstanding, as in the MMM17 national analyses, it is remarkable how often the various measures of hypertension detection and management are similar to previously available representative data.

A clear limitation of MMM, as a cross-sectional study, is the lack of definitive evidence of benefit for those individuals identified as having raised BP either on or off antihypertensive medication. The cost and logistic implications of incorporating follow-up of these screenees on such a large scale pre-empt our being able to do so. However, we know that about one-third of a million adults were given non-pharmacological lifestyle and dietary advice to lower their BPs and advised to obtain further follow-up of their BP measurement. We also know that MMM has generated significant coverage in traditional and social media outlets, and hopefully this will translate into increased awareness, treatment, and control and thereby reduced BP-associated disease burden.

Prospects for the MMM campaign
==============================

Both the numbers of countries and screenees involved with MMM have increased in each of the three annual campaigns to date. We plan to continue the campaign as long as funding can be raised with only small changes to the data collected each year. Meanwhile, we intend to use the MMM data for the development of documents designed to influence governments and health policymakers to improve the detection and management of raised BP at a national and international level.

Supplementary material
======================

[Supplementary material](#sup1){ref-type="supplementary-material"} is available at *European Heart Journal Supplements* online.

Supplementary Material
======================

###### 

Click here for additional data file.
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